Abstract:A hybrid virtual screening workflow, integrating methods such as Attentive FP, molecular docking, and molecular mechanics generalized Born surface area (MM/GBSA), was employed to identify a highly potent C‐terminal Src kinase (CSK) inhibitor, molecule 2. This compound demonstrated substantial growth suppression in various triple‐negative breast cancer cell lines and resulted in pronounced G1 phase accumulation and enhanced cell apoptosis. Oncogenic overexpression or activation of C‐terminal Src kinase (CSK) has been shown to play an important role in triple‐negative breast cancer (TNBC) progression, including tumor initiation, growth, metastasis, drug resistance. This revelation has pivoted the focus toward CSK as a potential target for novel treatments. However, until now, there are few inhibitors designed to target the CSK protein. Responding to this, our research has implemented a comprehensive virtual screening protocol. By integrating energy‐based screening methods with AI‐driven scoring functions, such as Attentive FP, and employing rigorous rescoring methods like Glide docking and molecular mechanics generalized Born surface area (MM/GBSA), we have systematically sought out inhibitors of CSK. This approach led to the discovery of a compound with a potent CSK inhibitory activity, reflected by an IC50 value of 1.6 nM under a homogeneous time‐resolved fluorescence (HTRF) bioassay. Subsequently, molecule 2 exhibits strong growth inhibition of MD anderson ‐ metastatic breast (MDA‐MB) ‐231, Hs578T, and SUM159 cells, showing a level of growth inhibition comparable to that observed with dasatinib. Treatment with molecule 2 also induced significant G1 phase accumulation and cell apoptosis. Furthermore, we have explored the explicit binding interactions of the compound with CSK using molecular dynamics simulations, providing valuable insights into its mechanism of action.

Discovery of novel small-molecule Src kinase inhibitors via a kinase-focused druglikeness rule and structure-based virtual screening

Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation

Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening

Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase

Identification of Novel Src, Bcl-2 Dual Inhibitors by the Pharmacophore Model, Molecular Docking, and Molecular Dynamics Simulations

Structure and Characterization of a Covalent Inhibitor of Src Kinase

Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.

Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Discovering New PI3Kα Inhibitors with a Strategy of Combining Ligand-Based and Structure-Based Virtual Screening.

Discovery of novel p90 ribosomal S6 kinase 2 inhibitors for potential cancer treatment through ligand-based and structure-based virtual screening methods

In Silico Investigation of Potential Src Kinase Ligands from Traditional Chinese Medicine

Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors

In Silico Approaches Using Pharmacophore Model Combined with Molecular Docking for Discovery of Novel ULK1 Inhibitors.

Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors.

Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening

Discovery of novel inhibitors disrupting HIF-1 alpha/von Hippel-Lindau interaction through shape-based screening and cascade docking